PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3518.1024-000			
IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro FILING DATE November 26,		26, 2003	
October 13, 2005 (Use several sheets if necessary)	EXAMINER Williams, Leonard M.	CONFIRMATI	ION NO.	GROUP 1617

TRANC			THE POSITION OF THE PARTY OF TH	
		U.S.	. PATENT DOCUMENTS	
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
CH	Αl	US 2003/0007972 A1	01-09-2003	Tobinick
CH	A2	6,554,830	04-29-2003	Chappius
C#	А3	US 2002/0010471 A1	01-24-2002	Wironen et al.
cH	A4	5,270,300	12-14-1993	Hunziker
c#	A5	5,942,499	08-24-1999	Radomsky
CH	A6	5,510,370	04-23-1996	Hock
C#	A7	6,590,081 B1	07-08-2003	Zhang
CH	A8	US 2002/0107200 A1	08-08-2002	Chang et al.
cut	A9	6,049,026	04-11-2000	Muschler
CH	A10	US 2003/0039651 A1	02-27-2003	Olmarker
CH	All	5,231,024	07-27-1993	Moeller et al.
CA#	A12	6,277,969 B1	08-21-2001	Le et al.
CAT	A13	5,447,851	09-05-1995	Beutler et al.
CA	A14	5,116,964	05-26-1992	Capon et al.
C#	AI5	5,225,538	07-06-1993	Capon et al.
C#	A16	6,541,477 B2	04-01-2003	Goehring et al.
C#	A17	5,965,583	10-12-1999	Beers et al.
C-H	A18	5,728,396	03-17-1998	Peery et al.
ct	A19	US 2003/0069639 A1	04-10-2003	Sander et al.
CH	A20	US 2003/0207827 A1	11-06-2003	Boyle et al.

EXAMINER Carla Hungh	DATE CONSIDERED 5/9/07	

1617

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

October 13, 2005

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 3518.1024-000	APPLICATION NO. 10/723,250
FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE November 26, 2003
EXAMINER	CONFIRMATION NO. GROUP

6059

		I	OREIGN PATENT D	OCUMENTS	
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
CH	Bl	WO 02/057240 A1	07-25-2002	Ortho McNeil Pharmaceutical, Inc.	
CH	B2	WO 91/02078	02-21-1991	Peptide Technology, Ltd.	
CH	В3	EP 0 218 868 A2	04-22-1987	New York Blood Center, Inc.	
CH	B4	EP 0 288 088 B1	10-26-1988	Teijin Limited	·
C#	B5	WO 92/07076	04-30-1992	The Charing Cross Sunley Research Centre	
C#	В6	WO 93/16099	08-19-1993	Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka MBH	
C#	B7	WO 99/45923	09-16-1999	Fisher et al.	
. cr	B8	EP 0 950 417 A2	02-15-1999	Pfizer Products Inc.	
	-				

Williams, Leonard M.

EXAMINER	M	Hung	h

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. APPLICATION NO. 10/723,250			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro FILING DATE November 26,		26, 2003	
October 13, 2005 (Use several sheets if necessary)	EXAMINER Williams, Leonard M.	CONF	IRMATION NO.	GROUP 1617

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
CH	С1	Pacifici, R., "Editorial: Cytokines, Estrogen, and Postmenopausal Osteoporosis-The Second Decade," Endocrinology, 139(6):2659-2661 (1998).			
CH	C2	Allali, F. et al., "Increase in Bone Mineral Density of Patients with Spondyloarthropathy Treated with Anti-Tumour Necrosis Factor α," Ann. Rheum. Dis., 62:347-349 (2003).			
·c#	C3	Tobinick, E.L., "Targeted Etanercept for Treatment-Refractory Pain Due to Bone Metastasis: Two Case Reports," Clin. Ther., 25(8):2279-2288 (2003).			
CH	C4	Biskobing, D.M., "Novel Therapies for Osteoporosis," Expert Opinion Invest. Drugs, 12(4):611-621 (2003).			
w	C5	Vahle, J.L. et al., "Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety," Toxicol. Pathol., 30(3):312-321 (2002).			
· C#	C6	Rodan, G.A. et al., "Therapeutic Approaches to Bone Diseases," Science, 289:1508-1514 (2000).			
CH	C7	Nakamura, K. et al., "Local Application of Basic Fibroblast Growth Factor into the Bone Increases Bone Mass at the Applied Site in Rabbits," Arch. Orthop. Trauma Surg., 115(6):344-346 (1996).			
CN	C8	Lane, N.E. et al., "Basic Fibroblast Growth Factor Forms New Trabeculae that Physically Connect with Pre-Existing Trabeculae, and This New Bone is Maintained with an Anti-Resorptive Agent and Enhanced with an Anabolic Agent in an Osteopenic Rat Model," Osteoporos. Int., 14:374-382 (2003).			
CH	C9	Goodman, S. et al., "Effects of Local Infusion of TGF\$\beta\$ on Bone Ingrowth in Rabbit Chambers," J. Biomed. Mat. Res. (Appl Biomater), 53:475-479 (2000).			
CH	C10	Pederson, A.W. et al., "Thermal Assembly of a Biomimetic Mineral/Collagen Composite," Biomaterials, 24:4881-4890 (2003).			
C#	C11	Kimble, R.B. et al., "Estrogen Deficiency Increases the Ability of Stromal Cells to Support Murine Osteoclastogenesis Via an InterLeukin-1 and Tumor Necrosis Factor-Mediated Stimulation of Macrophage Colony-Stimulating Factor Production," J. Biol. Chem. 271(46):28890-28897 (1996).			
CH	C12	Kimble, R.B. et al., "The Functional Block of TNF but Not of IL-6 Prevents Bone Loss in Ovariectomized Mice," J. Bone Min. Res., 12(6):935-941 (1997).			

EXAMINER Carlie Harych	DATE CONSIDERED 9/07</th

PTO-1449 REPRODUCED			LICATION NO. 723,250		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	1.1.0.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1		FILING DATE November	EDATE ember 26, 2003	
October 13, 2005	EXAMINER	1	RMATION NO.	GROUP	
(Use several sheets if necessary)	Williams, Leonard M. 6			1617	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CH	C13	Lee, J.C. et al., "Inhibition of p38 MAP Kinase as a Therapeutic Strategy," Immunopharmacology, 47:185-201 (2000).		
CH	C14	Boehm, J. and Adams, J., "New Inhibitors of p38 Kinase," Exp. Opin, Ther. Patents, 10(1):25-37 (2000).		
CH	C15	Kozbor, D. and Roder J., "The Production of Monoclonal Antibodies from Human Lymphocytes," <i>Immunol. Today</i> , 4:72-79 (1983).		
cu	C16	"Hydrogels", Encyclopedia of Polymer Science and Technology, (Wiley and Sons, 2003).		
C#	C17	Müller, R., "Determination of Affinity and Specificity of Anti-Hapten Antibodies by Competitive Radioimmunoassay," <i>Meth. Enzymol.</i> , 92:589-601 (1983).		
U	C18	Möller, A. et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor α: In Vitro and In Vivo Application," Cytokine, 2(3):162-169 (1990).		
ev	C19	Meager, A. et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," Hybridoma, 6(3):305-311 (1987).		
cu	C20	Fendly, B.M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," Hybridoma, 6(4):359-370 (1987).		
C#	C21	Bringman, T.S. et al., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes," Hybridoma, 6(5):489-507 (1987).		
CH	C22	Hirai, M. et al., "Production and Characterization of Monoclonal Antibodies to Human Tumor Necrosis Factor," J. Immunol. Meth., 96:57-62 (1987).		
c*	C23	Schall, T.J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," Cell, 61:361-370 (1990).		
CA	C24	Loetscher, H. et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," Cell, 61:351-359 (1990).		
C#	C25	Corcoran, A.E. et al., "Characterization of Ligand Binding by the Human p55 Tumour-Necrosis-Factor Receptor," Eur. J. Biochem., 223:831-840 (1994).		

EXAMINER Carla Hungh	DATE CONSIDERED \$/9/07
----------------------	-------------------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3518.1024-000	APPLICATION NO. 10/723,250			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE November	26, 2003		
October 13, 2005 (Use several sheets if necessary)	EXAMINER Williams, Leonard M.	CONFIRMATION NO. 6059	GROUP 1617		

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
CH	C26	Engelmann, H. et al., "Two Tumor Necrosis Factor-Binding Proteins Purified from Human Urine," J. Biol. Chem., 265(3):1531-1536 (1990).			
CH	C27	Lesslauer, W. et al., "Recombinant Soluble Tumor Necrosis Factor Receptor Proteins Protect Mice From Lipopolysaccharide-Induced Lethality," Eur. J. Immunol., 21:2883-2886 (1991).			
·c#	C28	Ashkenazi, A. et al., "Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin," Proc. Natl. Acad. Sci. USA, 88:10535-10539 (1991).			
cu	C29	Peppel, K. et al., "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," J. Exp. Med., 174:1483-1489 (1991).			
CA	C30	Kolls, J. et al., "Prolonged and Effective Blockade of Tumor Necrosis Factor Activity Through Adenovirus-Mediated Gene Transfer," Proc. Natl. Acad. Sci. USA, 91:215-219 (1994).			
· C#	C31	Butler, D.M. et al. "TNF Receptor Fusion Proteins are Effective Inhibitors of TNF-Mediated Cytotoxicity on Human KYM-1D4 Rhabdomyosarcoma Cells," Cytokine, 6(6):616-623 (1994).			
en	C32	Baker, D. et al., "Control of Established Experimental Allergic Encephalomyelitis by Inhibition of Tumor Necrosis Factor (TNF) Activity Within the Central Nervous System Using Monoclonal Antibodies and TNF Receptor-Immunoglobulin Fusion Proteins," Eur. J. Immunol., 24:2040-2048 (1994).			
CH	C33	Capon, D.J. et al., "Designing CD4 Immunoadhesins for AIDS Therapy," Nature, 337:525-531 (1989).			
ca	C34	Cirillo, P.F. et al., "The Non-Diaryl Heterocycle Classes of p38 MAP Kinase Inhibitors," Current Topics in Medicinal Chemistry, 2:1021-1035 (2002).			
en	C35	Zhang, C., "Mitogen-activated Protein (MAP) Kinase Regulates Production of Tumor Necrosis Factor-α and Release of Arachidonic Acid in Mast Cells," J. Biol. Chem., 272(20):13397-13402 (1997).			
en	C36	Pargellis, C., "Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site," Nature Structural Biology, 9(4):268-272 (2002).			
en	C37	Chae, H.J., "The p38 Mitogen-Activated Protein Kinase Pathway Regulates Interleukin-6 Synthesis in Response to Tumor Necrosis Factor in Osteoblasts," <i>Bone, 28</i> (1):45-53 (2001).			
C#	C38	DeSantis, A. and Buchman, A., "Current and Emerging Therapies in Osteoporosis," Expert Opin. Pharmacother., 3(7):835-843 (2002).			

EXAMINER Carles Huych	DATE CONSIDERED 5/9/07

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3518.1024-000		APPLICATION NO. 10/723,250		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE November 26, 2003		
October 13, 2005	EXAMINER	1	IRMATION NO.	GROUP	
(Use several sheets if necessary)	Williams, Leonard M.	6059		1617	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
CH	Nakamura, K. et al., "Stimulation of Endosteal Bone Formation by Local Intraosseous Application of Basic Fibroblast Growth Factor in Rats," Rev. Rhum. [Engl. Ed.], 64(2):101-105 (1997).				
CH	C40	Ezra, A., and Golomb, G., "Administration Routes and Delivery Systems of Bisphosphonates for the Treatment of Bone Resorption," Adv. Drug Del. Rev., 42:175-195 (2000).			
. CH	C41	Crandall, C., "Combination Treatment of Osteoporosis: A Clinical Review," J. of Women's Health & Gender-Based Medicine, 11(3):211-224 (2002).			
C#	C42	Yaffe, A. et al., "Combined Local Application of Tetracycline and Bisphosphonate Reduces Alveolar Bone Resporption in Rats," J. Periodontol, 74:1038-1042 (2003).			

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 20, 2006 MAR 2 7 2006 We Use several sheets if necessary)	ATTORNEY DOCKET NO. 3518.1024-000	APPLICATION NO. 10/723,250
	FIRST NAMED INVENTOR Thomas M. DiMauro	FILING DATE November 26, 2003
	EXAMINER Williams, Leonard M.	CONFIRMATION NO. GROUP 1617

	U.S. PATENT DOCUMENTS						
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT			
CH	A21	4,427,649	01-24-1984	Dingle, et al.			
ен	A22	5,095,037	03-10-1992	Iwamitsu, et al.			
cH	A23	5,368,841	11-29-1994	Trauner, et al.			
CH	A24	5,656,272	08-12-1997	Le, et al.			
CH	A25	5,833,984	11-10-1998	Eibl, et al.			
CH	A26	6,284,471	09-04-2001	Le, et al.			
est	A27	6,294,170	09-25-2001	Boone, et al.			
CH	A28	6,623,472	09-23-2003	Reinecke, et al.			
CH	A29	6,340,369 B1	01-22-2002	Ferree			
CH	A30	6,713,246	03-30-2004	Reinecke, et al.			
CH	A31	US 2001/0006948	07-05-2001	Kang, et al.			
CH	A32	US 2001/0016195 A1	07-05-2001	Tobinick			
CH	A33	US 2001/0026801	10-04-2001	Tobinick			
CH	A34	US 2002/0026244 A1	02-28-2002	Trieu			
CH	A35	US 2002/0032155 A1	03-14-2002	Ferree			
CH	A36	US 2002/0198599 A1	08-08-2002	Chang, et al.			
CH	A37	US 2003/0049256 A1	03-13-2003	Tobinick			
CH	A38	US 2003/0134792 A1	07-17-2003	Pike, et al.			
CH	A39	US 2004/0193274 A1	09-30-2004	Trieu			
C#	A40	US 2004/0229786 A1	11-18-2004	Attawia, et al.			
CH	A41	US 2005/0038001 A1	02-17-2005	Attawia, et al.			
CH	A42	US 2002/0169162	11-14-2002	Smith, et al.			
CH	A43	6,352,557 B1	03-05-2002	Ferree			
CH	A44	6,419,944	07-16-2002	Tobinick			

EXAMINER ()	DATE CONSIDERED
Carle Hungh	3/9/07

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 20, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3518.1024-000 APPLICATION NO. 10/723,250		
	FIRST NAMED INVENTOR Thomas M. DiMauro FILING DATE November 2		26, 2003
	EXAMINER Williams, Leonard M.	CONFI 6059	RMATION NO.

	FOREIGN PATENT DOCUMENTS						
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO		
CH	В9	EP 0 438 234 A1	07-24-1991	Kita			
CI	B10	EP 1 133 995 A2	09-19-2001	Synergen, Inc.			
CH	Bii	EP 1 153 607 A2	11-14-2001	Dunn			
C#	B12	EP 1 464 307 A1	10-06-2004	DePuy Spine, Inc.			
e#	B13	WO 2004/022078 A1	03-18-2004	The Royal Veterinary College			
eH	B14	WO 92/16553 A1	10-01-1992	New York University and Centocor, Inc.			
C#	B15	WO 97/28828 A1	08-14-1997	Amgen Boulder, Inc.			
CA	B16	WO 98/24477 A1	06-11-1998	Amgen, Inc.			
CH	B17	WO 01/85179 A2	11-15-2001	Clemson University			
eH	B18	WO 02/100387 A1	12-19-2002	A+ SCIENCE INVEST AB			
CH	B19	WO 03/000190 A2	01-03-2003	DePuy			
			·				
 							
 	 						
ļ	 						
							
	 						
				·			
	 						
	1						

EXAMINER Carlin Anyth	DATE CONSIDERED \$/9/07

@RFDesktop\-ODMA/MHODMA/HBSR05-iManage,605034-1

PTO-1449 REPRODUCED SUPPLEMENTAL	ATTORNEY DOCKET NO. 3518.1024-000		APPLICATION NO. 10/723,250	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 20, 2006 (Use several sheets if necessary)	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE November 26, 2003	
	EXAMINER Williams, Leonard M.	CONFI 6059	RMATION NO.	GROUP 1617

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
CH	C43	Abstracts of the North American Spine Society 17 Annual Meeting, Montreal, Canada, October 29 through November 2, 2002, The Spine Journal 2(5 Suppl):49S-50S (2002).
CH	C44	Ahn, N. U., et al., "Effect of Nutrient Concentration and OP-1 on the Metabolism of Intervertebral Disc: In Vitro Organ Culture Study," 28, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C45	Alini, M., et al., "A Biological Approach in Treating Disc Degeneration: Not for Today, but Maybe for Tomorrow," European Spine Journal, 11(Suppl 2):S215-S220 (2002).
CH.	C46	Andonopoulos, A. P., et al., "Intra-articular Anti-Tumor Necrosis Factor α Antibody in Recalcitrant Arthritis of Behçet's Disease," Clinical and Experimental Rheumatology 21(4 Suppl 30):S-57-S58 (July-August 2003).
CH	C47	Aoki, Y., et al., "Local Application of Disc-Related Cytokines on Spinal Nerve Roots," Spine 27(15): 1614-1617 (2002).
CA	C48	Arai, I., et al., "Pretreatment with Loxoprofen Sodium, 6-OHDA or Anti TNF-Alpha Antibody Reduce Fos-Like Immunoreactivity in Rat Experimental Lumber Disc Herniation," 111, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C49	Ariga, K., et al., "Mechanical Stress-Induced Apoptosis of Endplate Chondrocytes in Organ-Cultured Mouse Intervertebral Discs," Spine, 28(14):1528-1533 (2003).
CH	C50	Bokarewa, M., and Tarkowski, A., "Local Infusion of Infliximab for the Treatment of Acute Joint Inflammation," <i>Ann. Rheum. Dis.</i> , downloaded from ard.bmjjournals.com on 30 November 2005, www.annrheumdis.com 62:783-784 (2003).
CH	C51	Braun, J. and Sieper, J., "Overview of The Use of The Anti-TNF Agent Infliximab in Chronic Inflammatory Diseases," <i>Expert Opin. Biol. Ther.</i> 3(1):141-168 (2003).
CH	C52	Braun, J., et al., "Anti-Tumour Necrosis Factor α Therapy for Ankylosing Spondylitis: International Experience," Ann. Rheum. Dis., 61(Supp. III):iii51-iii60 (2002).

EXAMINER Carlie Huyuh	DATE CONSIDERED 5/9/07

@PFDesktoon ODMAMHODMA/HBSR05:iMana +c 605034-1-

PTO-1449 REPRODUCED SUPPLEMENTAL	Arrolate Bootles		application no. 10/723,250	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 20, 2006 (Use several sheets if necessary)	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE November 26, 2003	
	EXAMINER Williams, Leonard M.			GROUP 1617

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
C#	C53	Bringman, T.S., et al., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Application for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987).
CH	C54	Brown, K., et al., "Gelatin/Chondroitin 6-Sulfate Microspheres for the Delivery of Therapeutic Proteins to the Joint," Arthritis. & Rheum., 41(12):2185-2195 (1998).
CH	C55	Burke, J. G., et al., "Human Nucleus Pulposus Secretes Transforming Growth Factor Beta-1 and Basic Fibroblast Growth Factor," 189, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C56	Burke, J.G., et al., "Intervertebral Discs Which Cause Low Back Pain Secrete High Levels of Proinflammatory Mediators," J. Bone Joint Surg. [Br], 84-B, 196-201 (2002).
·CH	C57	Cardone, D.A., and Tallia, A.F., "Diagnostic and Therapeutic Injection of the Hip and Knee," Am. Fam. Physician, 67(10):2147-2152 (2003).
CH	C58	Connolly, J., et al., "Development of an Osteogenic Bone-Marrow Preparation," J. of Bone and Joint Surgery, Inc., 71-A (5):684-691 (1989).
Cat	C59	Conti, F., et al., "Successful Treatment With Intraarticular Infliximab for Resistant Knee Monarthritis in a Patient With Spondylarthropathy," Arthritis & Rheumatism, 52(4):1224-1226 (2005)
CH	C60	Cornefjord, M., et al., "Cerebrospinal Fluid Biomarkers in Experimental Spinal Nerve Root Injury," 38, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
СН	C61	Dayer, J.M., "The Pivotal Role of Interleukin-1 in the Clinical Manifestations of Rheumatoid Arthritis," Rheumatology, Oxford University Press, London, GB, 42(Suppl 2):ii3-ii10 (2003).
CH	C62	Diwan, A.D., et al., "Current Concepts in Intervertebral Disk Restoration," Tissue Engineering in Orthopedic Surgery, 31(3):453-464 (2000).

EXAMINER	0	0	$\overline{}$	1
	Car	lu_	duy	nh

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 20, 2006 (Use several sheets if necessary)			APPLICATION NO. 1 0/723,250	
			FILING DATE November 26, 2003	
	EXAMINER Williams, Leonard M.	6059	RMATION NO.	GROUP 1617

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
CH	C63	Edwards, S. L., et al., "Radiographic Assessment of Posterolateral Spine Fusion With and Without Platelet Rich Plasma," 117, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C64	Eustice, Carol & Richard, "What is Viscosupplementation?" http://arthritis.com/od/kneetreatments/g/viscosupplement_p.htm , 12/9/05.
CH	C65	Frain, J., et al., "Use of cDNA Microarrays to Investigate Cytokine Expression in Intervertebral Disc Degeneration," 126, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C66	Gabay, C., "IL-1 Trap," Curr. Opin. Invest. Drugs, Curr. Drugs, London, GB, 4(5):593-597 (2003).
CH	C67	Ganey, T.M., and Meisel, H.J., "A Potential Role for Cell-Based Therapeutics in the Treatment of Intervertebral Disc Herniation," Eur. Spine J., 11 (Suppl. 2): S206-S214 (2002).
CH	C68	Gordon, J.L., et al., "Metalloproteinase Inhibitors as Therapeutics," Clin. Exp. Rheumatol., 11(Suppl. 8): S91-S94 (1993).
CH	C69	Goupille, P., et al., "Matrix Metalloproteinases: The Clue to Intervertebral Disc Degeneration?," Spine, 23(14): 1612-1626 (1998).
Сн	C70	Kawakami, M., et al., "Role of IL-8, MCP-1 and PH in Neuropathic Pain Enhanced by Degenerative Nucleus Pulposus," 127, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CI	C71	Hunter, C. J., et al., "Functional Behavior of Notochordal Cell Clusters in the Canine Nucleus Pulposus: Cell Communication and Survival," 70, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
a	C72	Igarashi, A., et al., "Inflammatory Cytokines Release From Facet Joint Tissue in Degenerative Lumbar Disorders," 262, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).

EXAMINER /	DATE CONSIDERED	×19/07	
Carle Hugh		3/1/01	
@3-1 Pricus UJNOW-UJNOCARSTOS V. REUSINI			

PTO-1449 REPRODUCED SUPPLEMENTAL			dPLICATION NO. 0/723,250		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	I FIRST MANIED INVENTOR		FILING DATE November 2		
March 20, 2006 (Use several sheets if necessary)	EXAMINER Williams, Leonard M.	CONFI 6059	IRMATION NO.	GROUP 1617	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
C#	C73	Imai, Y., et al., "Effect of Recombinant Human Osteogenic Protein-1 on Extracellular Matrix Metabolism by Human Annulus Fibrosus and Nucleus Pulposus Cells," 205, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C74	Imai, Y., et al., "The Quantification of Cytokine-Induced Matrix Catabolism in Tissue Engeneered Intervertebral Discs," 67, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C75	Inui, Y., et al., "Fas-Ligand Expression on Nucleus Pulposus Cells Begins in Developing Embryo," 42, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C76	Johnson, W.H., et al., "Collagenase Inhibitors: Their Design and Potential Therapeutic Use," J. Enzyme Inhib., 2:1-22 (1987).
C#	C77	Karppinen, J., et al., "Tumor Necrosis Factor- α Monoclonal Antibody, Infliximab, Used to Manage Severe Sciatica," Spine, 28(8):750-754 (2003).
CH	C78	Kato, H., et al., "The Effect of IL-1 on the Rabbit Intervertebral Disc In Vivo," 199, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C79	Kawakami, M., et al., "Possible Mechanism of Painful Radiculopathy in Lumbar Disc Herniation," Clin. Orthop., 351:241-251(1998).
CA	C80	Koch, H., et al., "Spontaneous Secretion of Interleukin 1 Receptor Antagonist (IL-1Ra) by Cells Isolated From Herniated Lumbar Discal Tissue After Discectomy," Cytokine, 10(9):703-705 (1998).
CH	C81	Ohtori, S., et al., "TNF-\alpha Deficient Mice Have Fewer Macrophages in Injured Nerve and Reduced Glial Activation in DRG and Spinal Cord," 250, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).

EXAMINER Call Hugh	DATE CONSIDERED 5/9/07

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION March 20, 2006 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3518.1024-000		APPLICATION NO. 10/723,250		
	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE November 26, 2003		
	EXAMINER Williams, Leonard M.	CONFI 6059	RMATION NO.	GROUP 1617	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
CH	C82	Korhonen, T., et al., "Efficacy of Infliximab for Disc Herniation-Induced Sciatica One-Year Follow-Up," 14, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C83	Kwon, U-H., et al., "Dexamethsone Stimulates Cellular Proliferation While Downregulates Matrix Synthesis in Intervertebral Disc Cells," 29, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CĤ.	C84	Lane, N.E. et al., "Basic Fibroblast Growth Factor Forms New Trabeculae That Physically Connect With Pre-Existing Trabeculae, and This New Bone is Maintained With an Anti-Resorptive Agent and Enhanced With an Anabolic Agent in an Osteopenic Rat Model," Osteoporos. Int., 14:374-382 (2003).
CH	C85	LaVan, D. A., et al., "Small-scale Systems for in vivo Drug Delivery," Nature, Biotechnology, 21(10):1184-1191 (2003).
CH	C86	Lee, C. S., et al., "A Single Period of Hyperphysiologic Stretch Induces IL-6, TGF-beta and Cell Proliferation in Anulus Fibrosus Cells," 215, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C87	Lehman, T. J. A., et al., "Thalidomide Therapy for Recalcitrant Systemic Onset Juvenile Rheumatoid Arthritis," J. Pediatrics, 140(1):125-127 (2002).
CH	C88	Le Maitre, C. L., et al., "Expression of the IL-1 Family in Human Intervertebral Disc," 217, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C89	Le Maitre, C. L., et al., "Response of Human Intervertebral Disc Cells to IL-1," 216, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C90	Le Visage, C., et al., "Interaction of Human Mesenchymal Stem Cells with Disc Cells: Changes in Biosynthesis of Extracellular Matrix," 25, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).

EXAMINER Carles Drugsch	DATE CONSIDERED 5/9/07

PTO-1449 REPRODUCED SUPPLEMENTAL			APPLICATION NO. 10/723,250		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE November 26, 2003		
March 20, 2006 (Use several sheets if necessary)	EXAMINER Williams, Leonard M.	CONFI 6059	RMATION NO.	GROUP 1617	

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
CH	C91	Li, J., et al., "The Effects of Bone Morphogenetic Protein 2 (BMP-2) and Cartilage-Derived Morphogentic Protein 2 (CDMP-2) on Aggrecan Gene Expression in Chondrocytes," 30, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C92	Liang, CM., et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," Biochem. Biophys. Res. Comm. 137 (2):847-854 (1986).
CH .	C93	Lotz, J. C., et al., "Cytokines in Normal, Degenerated, and Nucleoplasty-Treated Porcine Discs," 157, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CA	C94	Maeda, S. and Kokubun, S., "Changes With Age in Proteoglycan Synthesis in Cells Cultured In Vitro From the Inner and Outer Rabbit Annulus Fibrosus," Spine, 25(2):166-169 (2000).
CH	C95	Meijer, H., et al., "The Production of Anti-Inflammatory Cytokines in Whole Blood by Physico-Chemical Induction," <i>Inflamm. Res.</i> , 52: 404-407 (2003).
CH	C96	Miyamoto, H., et al., "The Effect of Mechanical Stress on the Production of Inflammatory Agents by Disc Cells," 110, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C97	Sakai, D., et al., "Autologous Transplantation of Mesenchymal Stem Cells for Disc Repair," 24, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C98	Molloy, T., et al., "The Roles of Growth Factors in Tendon and Ligament Healing," Sports Med., 33(5): pp.381-394 (2003).
CH	C99	Nikas, S. N., et al., "Treatment of Resistant Rheumatoid Arthritis by Intra-Articular Infliximab Injections: A Pilot Study," Ann. Rheum. Dis., downloaded from ard.bmjjournals.com on 2 November 2005, www.annrheumdis.com 63: 102-103 (2004).

EXAMINER Carlie Houpe	DATE CONSIDERED \$/9/07

O-1449 REPRODUCED SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION			application no. 10/723,250	
IN AN APPLICATION			FILING DATE November 26, 2003	
March 20, 2006 (Use several sheets if necessary)	EXAMINER Williams, Leonard M.	CONFI 6059	RMATION NO.	GROUP 1617

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
CH	C100	Ohtori, S., et al., "TNF-\alpha and TNF-\alpha Receptor 1 Upregulation in GLIA and Neurons After Nerve Injury. Studies in Murine DRG and Spinal Cord," 13, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
eH	C101	Olmarker, K. and Rydevik, B., "Selective Inhibition of Tumor Necrosis Factor- \alpha Prevents Nucleus Pulposus-Induced Thrombus Formation, Intraneural Edema, and Reduction of Nerve Conduction Velocity," Spine, 26(8):863-869 (2001).
CH	C102	Richardson, S., et al., "Human Bone Marrow Mesenchymal Stromal Cells as a Source of Chondrocytes for Treatment of Intervertebral Disc Degeneration," 27, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
C#	C103	Sakai, D., et al., "Transplantation of Mesenchymal Stem Cells Embedded in Atelocollagen® Gel to the Intervertebral Disc: A Potential Therapeutic Model for Disc Degeneration," Biomaterials, 24:3531-3541 (2003).
OH	C104	Schatteman, L., et al., "Treatment of Refractory Inflammatory Monoarthritis in Ankylosing Spondylitis by Intraarticular Injection of Infliximab," J. Of Rheum., 33:1:82-85 (2006).
CH	C105	Sobajima, S., et al., "Stem Cell Therapy for Degenerative Disc Disease: An In-Vitro Feasibility Study," 43, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C106	Stern, S., et al., "Human Intervertebral Disc Cell Culture for Disc Disorders," Clin. Orthop., 419:238-244 (2004).
CH	C107	Takada, T., et al., "IL-6 Production was Upregulated by Interaction Between Disc Tissue and Macrophages," 41, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C108	Takegami, K. et al., "Osteogenic Protein-1 Enhances Matrix Replenishment by Intervertebral Disc Cells Previously Exposed to Interleukin-1," Spine, 27(12):1318-1325 (2002).

EXAMINER Carlie Huyuh	DATE CONSIDERED \$/9/67

PTO-1449 REPRODUCED SUPPLEMENTAL			1723,250	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro		FILING DATE November 26, 2003	
March 20, 2006 (Use several sheets if necessary)	EXAMINER Williams, Leonard M.	CONFI 6059	RMATION NO.	GROUP 1617

		OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
C#	C109	Tobinick, E.L., "Targeted Etanercept for Discogenic Neck Pain: Uncontrolled, Open-Label Results in Two Adults," Clin. Ther., 25(4):1211-1218 (2003).
CH	C110	Tobinick, E.L. and Davoodifar, S., "Perispinal TNF-alpha Inhibition for Discogenic Pain," Swiss Med. Weekly, 133:170-177 (2003).
CH	CIII	Tsuji, T., et al., "Age-Related Changes in M-RNA Expression of Various Regulatory Factors in Rabbit Intervertebral Disc," 81, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C112	Weiler, C., et al., "Expression of TNF- α in Autopsy and Biopsy Specimens of Intervertebral Discs of Various Age and Degeneration," 233, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CA	C113	Wittenberg, R.H., et al., "In Vitro Release of Prostaglandins and Leukotrienes From Synovial Tissue, Cartilage, and Bone in Degenerative Joint Diseases," Arthritis Rheum., 36(10):1444-1450 (1993).
C#	C114	Xie, X., et al., "Treatment of Spondylodiscitis Intravenous Versus Percutaneous Intradiscal Applications of Antibiotics: An Experimental Study in Rabbits," 120, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).
CH	C115	Yabuki, S., et al., "Prevention of Compartment Syndrome in Dorsal Root Ganglia Caused by Exposure to Nucleus Pulposus," Spine, 26(8):870-875 (2001).
cs	C116	Yoon, S. T., et al., "LMP-1 Upregulates Proteoglycan Synthesis in Intervertebral Disc Cells Through a BMP Mediated Process," 31, Abstracts of the 30th Annual Meeting of the International Society for the Study of the Lumbar Spine, Vancouver, Canada (May 2003).

EXAMINER	 he	Huynh

1449 REPRODUCED	ATTORNEY DOCKET NO. 3518.1024-000	1	LICATION NO. 723,250		
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	1		FILING DATE November :	ing date ovember 26, 2003	
September 15, 2006 SEP 2 1 2006 September 15, 2006	EXAMINER Leonard M. Williams	CONFI 6059	RMATION NO.	GROUP 1617	

TAY A	U.S. PATENT DOCUMENTS						
EXAM- INER INI- TIAL		DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT			
CH	A45	6,756,215 B1	06-29-2004	Wolfraim et al.			
CH	A46	5,194,596	03-16-1993	Tischer et al.			
CH	A47	2002/0082697 A1	06-27-2002	Damien			
CH	A48	2004/0022864 A1	02-05-2004	Freyman et al.			
CH	A49	2004/0126372 A1	07-01-2004	Banerjee et, al.			
CH	A50	6,340,369 B1	01-22-2002	Ferree			

	FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	NT TRANSLATION YES NO				
CH	B20	WO 2005/110276 A1	11-24-2005	Massachusetts General Hospital					
CH	B21	WO 2005/000283 A2	01-06-2005	DePuy Spine, Inc.					
CH	B22	WO 2006/031376 A2	03-23-2006	DePuy Spine, Inc.					

	OTHER DOCUMENTS (Including Author, Title, Date, Perlinent Pages, Etc.)						
C#	C117	Hawks, D., "Alternative Medicine: Musculoskeletal System," Clin. Tech. Small Anim. Pract., 17(1):41-49 (2002).					
CH	C118	Khot, A. et al., "The Use of Intradiscal Steroid Therapy for Lumbar Spinal Discogenic Pain - A Randomized Controlled Trial," Spine, 29(8):833-837 (2004).					
CA	C119	Földes, I. et al., "Trace Elements in Tissues of Normal and Vitamin D ₂ -Treated Rats," ACTA Biol. Acad. Sci. Hung., 26(3-4):141-150 (1975).					
CH	C120	Benjamin, L.E. et al., "A Plasticity Window for Blood Vessel Remodelling is Defined by Pericyte Coverage of the Preformed Endothelial Network and is Regulated by PDGF-B and VEGF," <i>Development</i> , 125:1591-1598 (1998).					
ex	C121	Vukicevic, S. et al., "Induction of Nephrogenic Mesenchyme by Osteogenic Protein 1 (Bone Morphogenetic Protein 7)," Proc. Natl. Acad. Sci., 93:9021-9026 (1996).					

EXAMINER CALL THE STATE OF THE	DATE CONSIDERED
Carlie Hugh	3/4/01

PT 1-1449 REPRODUCED	ATTORNEY DOCKET NO. 3518.1024-000 APPLICATION NO. 10/723,250			
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro			26, 2003
September 15, 2006 (Use several sheets if necessary)	EXAMINER Leonard M. Williams	CONF	IRMATION NO.	GROUP 1617

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
CH	C122	Moreira, A.L. et al., "Thalidomide Exerts Its Inhibitory Action on Tumor Necrosis Factor α by Enhancing mRNA Degradation," J. Exp. Med., 177:1675-1680 (1993).				
CH	C123	CN 1 647 808 A (Zhou C) 2005-08-03 (abstract) World Patents Index [online]. London, GB: Derwent Publications, Ltd., Week 200621, Class B04, Accession No. 2006-194507.				
CH	C124	CN 1 569 039 A (Niu X) 2005-01-26 (abstract) World Patents Index [online]. London, GB: Derwent Publications, Ltd., Week 200577, Class B04, Accession No. 2005-749289.				
CH	C125	Shiel, W.C., Ankylosing Spondylitis, MedicineNet.com [online], September 2005 [retrieved on 2006-06-20]. Retrieved from the Internet <url: art.asp?articlekey="274&pf=3&page=2" http:="" main="" script="" www.medicinenet.com="">.</url:>				
CH	C126	Sampaio, E.P. et al, "Thalidomide Selectively Inhibits Tumor Necrosis Factor α Production by Stimulated Human Monocytes," J. Exp. Med., 173:699-703 (1991).				
CH	C127	Muller, G.W. et al., "Amino-Substituted Thalidomide Analogs: Potent Inhibitors of TNF-α Production," Bioorg. Med. Chem. Lett., 9:1625-1630 (1999).				
c#	C128	Teo, S.K., "Properties of Thalidomide and its Analogues: Implications for Anticancer Therapy," AAPS Journal 7(1):E14-E19 (2005).				
Cif	C129	Crevensten, G. et al., "Intervertebral Disc Cell Therapy for Regeneration: Mesenchymal Stem Cell Implantation in Rat Intervertebral Discs," Ann. Biomed. Eng., 32(3):430-434 (2004).				
CH	C130	Tracey, K.J. and Cerami, A., "Tumor Necrosis Factor in Metabolism of Disease: Hormonal Actions Versus Local Tissue Effects," Nouv. Rev. Fr. Hematol., 34 Suppl:S37-42 (1992) (abstract).				

EXAMINER Carlie Heumh	DATE CONSIDERED
	. 3/ //

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3518.1024-000	APPLICATION NO. 10/723,250		
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Thomas M. DiMauro FILING DATE November		26, 2003	
October 3, 2006 OCT 1 7 2006(Use several sheets if necessary)	EXAMINER Leonard M. Williams	CONFT 6059	RMATION NO.	GROUP 1617

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CH

C131

Haro, H. et al., "Matrix Metalloproteinase-7-Dependent Release of Tumor Necrosis Factor-α in a Model of Herniated Disc Resorption," J. Clin. Invest., 105(2):143-150 (2000).

EXAMINER Carle Huynh

DATE CONSIDERED

6/9/07

PE SUPLEMENTAL INFORMATION	ATTORNEY DOCKET NO. 3518.1024-000 FIRST NAMED INVENTOR Thomas M. DiMauro		APPLICATION NO. 10/723,250 FILING DATE November 26, 2003	
DISCLOSURE STATEMENT EB 1 A 2001 WIN AN APPLICATION				
February 9, 2007	EXAMINER Leonard M. Williams	CONFI 6059	RMATION NO.	GROUP 1617
(Use several sheets if necessary)			_	

	•	U.S.	. PATENT DOCUMENT	S
EXAM -INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
CH	A51	2005/0282783 A I	12-22-2005	Bujoli et al.

EXAMINER DATE CONSIDERED 5/9/07